If polymorphs of the neutral chemical asset do not exist, do not provide the desired properties, or do not solve solubility, stability, crystallinity, handling, or manufacturability problems, an ionizable molecule may require a pharmaceutical salt screen.
Pharmaceutically acceptable counterions are selected using the API pKa, prior clinical and market use, toxicology, screening precedent, regulatory expectations, and intended route of administration. The goal is not merely to make a salt, but to identify a salt that can be crystallized, characterized, controlled, formulated, and justified.
Useful salt forms can improve crystallinity, solubility, dissolution, stability, and manufacturability. However, salt forms can also create hydrate/solvate, hygroscopicity, morphology, or disproportionation risks that must be evaluated before the selected form anchors tox, clinical, or product decisions.
| Salt-selection driver | What must be tested | Decision output |
|---|---|---|
| Ionizable API with poor solubility | Counterion set, pH-solubility, crystalline salt formation, slurry conversion, dissolution, and residual-solid analysis. | Salt candidates ranked by solubility, crystallinity, stability, and developability. |
| Stability or handling problem | Humidity stress, DVS, hydrate/solvate checks, thermal behavior, microscopy, XRPD/Raman/IR fingerprints. | Selected salt with stress behavior and open-risk statement. |
| Formulation pH or excipient risk | Disproportionation testing under water activity, pH microenvironment, and formulation-relevant excipients. | Formulation-control recommendation and monitoring method. |
A defensible salt-selection package should also state why rejected salts were rejected. Poor crystallinity, unstable hydration, rapid disproportionation, unacceptable hygroscopicity, poor isolation, problematic morphology, or weak analytical specificity can be more important than an early solubility advantage.
A salt can revert toward the neutral free acid or free base if local pH, water activity, excipients, or counterion environment favor the neutral form. The result can be lower apparent solubility, altered dissolution, instability, or crystallization of the free form.
This risk is highest when the salt is marginally stable, the formulation contains hygroscopic or pH-modifying excipients, or processing introduces water. For this reason, salt screening should be connected to drug-product conditions rather than evaluated only as neat API.
Disproportionation risk should be treated as a solid-form and formulation problem together. A neat API result can miss the local pH and water-activity effects created by excipients, granulation fluid, residual solvent, or packaging conditions.
Salt selection starts with ionization chemistry, but the selection decision is broader than pKa. The program has to choose a form that can be made reproducibly, characterized unambiguously, formulated safely, and controlled through humidity, solvent, excipient, processing, and storage conditions.
Triclinic connects counterion choice to developability: crystallinity, solubility, dissolution, hygroscopicity, hydrate or solvate risk, morphology, disproportionation, analytical specificity, and downstream manufacturing needs.
Use this decision tree to connect form selection, form control, formulation, process development, method development, release testing, stability, and lifecycle risk before the examples and publications section.
Salt selection can be an efficient exposure-rescue path for an ionizable API, but a salt should not be selected only because it forms quickly or dissolves faster in a first experiment. Counterion acceptability, delta pKa logic, route, drug loading, crystallinity, manufacturability, hygroscopicity, disproportionation, and polymorphism within the salt all affect developability.
The practical question is whether the salt can be isolated, dried, milled, formulated, stored, monitored, and reproduced without reverting toward the free acid or free base under product-relevant microenvironments.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Crystallinity | Poorly crystalline salts can be difficult to isolate, dry, mill, or release reproducibly. | Confirm by XRPD, microscopy, DSC/TGA, and lot reproducibility. |
| Hygroscopicity | Water uptake can drive deliquescence, hydrate formation, poor flow, or packaging burden. | Use DVS, controlled-RH stress, water-content testing, and post-stress form ID. |
| Disproportionation | Local pH, water activity, and excipients can push a salt toward the neutral form. | Test excipient compatibility, wet-process stress, dissolution, and residual solids. |
| Salt polymorphism | The chosen salt may have multiple forms with different properties. | Run a salt-specific polymorph screen and thermodynamic ranking. |
Salt and cocrystal classification can depend on proton position, ionization state, and crystal-structure evidence. The same API/coformer pair may sit near a salt-cocrystal continuum, making structural and spectroscopic interpretation important for regulatory and IP decisions.
Triclinic links XRPD, Raman/IR, ssNMR, thermal analysis, microscopy, solubility, and crystallization behavior to the practical question: is the selected form developable and controllable under the intended product conditions?
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceUse coformer selection, phase-diagram logic, crystallization methods, and formulation strategy to improve properties and expand solid-form options.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceWhen the API is ionizable and the neutral form does not meet solubility, stability, crystallinity, manufacturability, or handling needs.
Counterions are selected from pharmaceutically acceptable options using API chemistry, pKa, toxicology and regulatory precedent, prior clinical use, and screening experience.
Because salt performance can change under humidity, local pH, excipient, vehicle, and processing conditions, especially if disproportionation is possible.
A salt screen can make a long candidate list quickly, but a long list is not the deliverable. The useful deliverable is a ranked, evidence-backed decision about which salt can be crystallized, characterized, formulated, and controlled. Counterion selection should not be based only on pKa or a standard list. Hydrates, solvates, hygroscopicity, particle habit, excipient microenvironment, and salt disproportionation can invalidate an attractive early hit. The selected salt must be tested against the real development context: formulation pH, water activity, process solvents, storage conditions, and the analytical method that will monitor the form.
Disproportionation risk is evaluated under relevant pH, water activity, humidity, excipient, solvent, processing, and storage conditions using phase-specific analytical methods rather than solubility data alone.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
